Skip to content

Medical emergency? What to do

New drug ups survival in advanced colon cancer

3-RXPublished April 4, 20062 min read

Key points

  • "Panitumumab is a new important treatment option for patients with chemo-resistant colorectal cancer, and it can add to the survival of these patients and their quality of life," researcher Dr.
  • In the study of 463 highly pre-treated patients with chemo-resistant colorectal cancer, those who were given panitumumab plus best supportive care showed a 46 percent decrease in the rate of tumor progression compared with patients who received best supportive care only.
  • Anderson Cancer Center in Houston who was not involved in the trial said one "distinguishing feature" of the trial was that the effect of panitumumab was obvious "early on, where patients on best supportive care alone were either failing or dying very quickly."
  • Last week, Amgen Inc., which is developing panitumumab with Abgenix Inc., a biotechnology company it is in the process of acquiring, announced it has applied for U.S.

Among patients with colorectal cancer that has spread to other areas of the body and who have not been helped by standard chemotherapy, a new drug called panitumumab produces a highly significant improvement in time without worsening of disease, according to data released at the annual meeting of the American Association for Cancer Research.

"Panitumumab is a new important treatment option for patients with chemo-resistant colorectal cancer, and it can add to the survival of these patients and their quality of life," researcher Dr. Marc Peeters from University Hospital Ghent in Belgium said at a press briefing.

Panitumumab targets a growth factor receptor that is a key player in cancer cell growth.

In the study of 463 highly pre-treated patients with chemo-resistant colorectal cancer, those who were given panitumumab plus best supportive care showed a 46 percent decrease in the rate of tumor progression compared with patients who received best supportive care only.

By the first scheduled assessment at week 8, significantly more panitumumab-treated patients were alive without progression (49 percent) than those receiving only supportive care (30 percent). "A difference in the percentage of patients alive favoring panitumumab continued through week 32," the research team reported.

Commenting on the results, Dr. James L. Abbruzzese from M.D. Anderson Cancer Center in Houston who was not involved in the trial said one "distinguishing feature" of the trial was that the effect of panitumumab was obvious "early on, where patients on best supportive care alone were either failing or dying very quickly."

Panitumumab was well tolerated with very few major adverse events and no treatment-related deaths. The most common side effect was skin rash seen in the majority of patients, but less than 1 percent discontinued treatment because of this. Other side effects included fatigue, nausea and diarrhea.

Last week, Amgen Inc., which is developing panitumumab with Abgenix Inc., a biotechnology company it is in the process of acquiring, announced it has applied for U.S. Food and Drug Administration approval of the drug for colon cancer.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underCancer

Keep reading

Brain

Italy court ruling links mobile phone use to tumor

Italy's supreme court has upheld a ruling that said there was a link between a business executive's brain tumor and his heavy mobile phone usage, potentially opening the door to further legal claims. The court's…

2 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.